Removal of limited nodal disease in patients undergoing radical prostatectomy: Long-term results confirm a chance for cure

Journal of Urology

Volumn 191, Issue 5, 2014, Pages 1280-1285

  Seiler, Roland ^a   Studer, Urs E ^a   Tschan, Konrad ^a   Bader, Pia ^a   Burkhard, Fiona C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

lymphatic metastasis; prostatectomy; prostatic neoplasms; treatment outcome

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; DISEASE COURSE; FOLLOW UP; HISTOLOGY; HUMAN; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; RELAPSE; SURVIVAL RATE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CONTROLLED STUDY; GLEASON SCORE; HEART FAILURE; HUMAN TISSUE; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PROGRESSION FREE SURVIVAL; RADICAL RETROPUBIC PROSTATECTOMY;

LYMPHATIC METASTASIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

EID: 84899111644     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.11.029     Document Type: Article

References (28)

1. M. Triantafyllou, U.E. Studer, and F.D. Birkhäuser et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer Eur J Cancer 49 2013 616
2. J.S. Wolf Jr., M. Cher, and M. Dall'era et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy J Urol 153 1995 993
3. A. Briganti, M.L. Blute, and J.H. Eastham et al. Pelvic lymph node dissection in prostate cancer Eur Urol 55 2009 1251
4. S.H. Warncke, A. Mattei, and F.G. Fuechsel et al. Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging Eur Urol 52 2007 126
5. F. Wawroschek, H. Vogt, and D. Weckermann et al. Radioisotope guided pelvic lymph node dissection for prostate cancer J Urol 166 2001 1715
6. J.E. Fowler Jr., and W.F. Whitmore Jr. The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer Cancer 47 1981 2941
7. H. Zincke Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome Urology 33 1989 27
8. F. Abdollah, M. Sun, and J. Schmitges et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics J Urol 188 2012 73
9. M. Han, A.W. Partin, and C.R. Pound et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
10. B.S. Carver, F.J. Bianco Jr., and P.T. Scardino et al. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer J Urol 176 2006 564
11. L.F. Da Pozzo, C. Cozzarini, and A. Briganti et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003
12. S.A. Boorjian, R.H. Thompson, and S. Siddiqui et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era J Urol 178 2007 864
13. A. Briganti, J.R. Karnes, and L.F. Da Pozzo et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy Eur Urol 55 2009 261
14. E.M. Messing, J. Manola, and M. Sarosdy et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781
15. U. Zwergel, J. Lehmann, and B. Wullich et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy J Urol 171 2004 1128
16. P. Bader, F.C. Burkhard, and R. Markwalder et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169 2003 849
17. L.H. Sobin, and C. Wittekind TNM Classification of Malignant Tumours, 6th Edition 2002 Wiley-Liss New York
18. M.E. Allaf, G.S. Palapattu, and B.J. Trock et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer J Urol 172 2004 1840
19. A. Heidenreich, Z. Varga, and R. Von Knobloch Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis J Urol 167 2002 1681
20. M.C. Schumacher, F.C. Burkhard, and G.N. Thalmann et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy Eur Urol 54 2008 344
21. S.V. Carlsson, L.J. Tafe, and D.C. Chade et al. Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer J Urol 189 2013 1314
22. G.D. Steinberg, J.I. Epstein, and S. Piantadosi et al. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987 J Urol 144 1990 1425
23. A. Fleischmann, S. Schobinger, and M. Schumacher et al. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases Prostate 69 2009 352
24. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind TNM Classification of Malignant Tumours, 7th Edition 2009 Wiley-Blackwell New York
25. A. Mattei, F.G. Fuechsel, and N. Bhatta Dhar et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study Eur Urol 53 2008 118
26. C.R. Pound, A.W. Partin, and J.I. Epstein et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control Urol Clin North Am 24 1997 395
27. N.L. Keating Medicare reimbursement and prescribing hormone therapy for prostate cancer J Natl Cancer Inst 102 2010 1814
28. U.E. Studer, L. Collette, and P. Whelan et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941